Next Article in Journal
Nanoparticle-Based mRNA Vaccine Induces Protective Neutralizing Antibodies Against Infectious Bronchitis Virus in In-Vivo Infection
Previous Article in Journal
Long-Term Immuno-Response and Risk of Breakthrough Infection After SARS-CoV-2 Vaccination in Kidney Transplantation
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella

1
State Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Graduate School, Clinical Laboratory Diagnostics, Urumqi 830000, China
2
Reproductive Fertility Assistance Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
3
Department of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi 830000, China
4
Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
*
Authors to whom correspondence should be addressed.
Vaccines 2025, 13(6), 567; https://doi.org/10.3390/vaccines13060567 (registering DOI)
Submission received: 31 March 2025 / Revised: 21 May 2025 / Accepted: 22 May 2025 / Published: 26 May 2025
(This article belongs to the Special Issue Animal Infectious Diseases and Vaccinology in One Health)

Abstract

Background: Brucellosis poses a significant public health challenge, necessitating effective vaccine development. Current vaccines have limitations such as safety concerns and inadequate mucosal immunity. This study aims to develop an FcRn-targeted mucosal Brucella vaccine by fusing the human Fc domain with Brucella’s multi-epitope protein (MEV), proposing a novel approach for human brucellosis prevention. Methods: The study developed a recombinant antigen (h-tFc-MEV) through computational analyses to validate antigenicity, structural stability, solubility, and allergenic potential. Molecular simulations confirmed FcRn binding. The vaccine was delivered orally via chitosan nanoparticles in murine models. Immunization was compared to MEV-only immunization. Post-challenge assessments were conducted to evaluate protection against Brucella colonization. Mechanistic studies investigated dendritic cell activation and antigen presentation. Results: Computational analyses showed that the antigen had favorable properties without allergenic potential. Molecular simulations demonstrated robust FcRn binding. In murine models, oral delivery elicited enhanced systemic immunity with elevated serum IgG titers and amplified CD4+/CD8+ T-cell ratios compared to MEV-only immunization. Mucosal immunity was evidenced by significant IgA upregulation across multiple tracts. Long-term immune memory persisted for six months. Post-challenge assessments revealed markedly reduced Brucella colonization in visceral organs. Mechanistic studies identified FcRn-mediated dendritic cell activation through enhanced MHC-II expression and antigen presentation efficiency. Conclusions: The FcRn-targeted strategy establishes concurrent mucosal and systemic protective immunity against Brucella infection. This novel vaccine candidate shows potential for effective human brucellosis prevention, offering a promising approach to address the limitations of current vaccines.
Keywords: FcRn: neonatal Fc receptor; MEV: multi-epitope vaccine; mucosal vaccine FcRn: neonatal Fc receptor; MEV: multi-epitope vaccine; mucosal vaccine
Graphical Abstract

Share and Cite

MDPI and ACS Style

Tian, T.; Zhu, Y.; Shang, K.; Shi, H.; Xu, R.; Li, M.; Pu, F.; Kuang, J.; Ding, J.; Zhang, F. FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella. Vaccines 2025, 13, 567. https://doi.org/10.3390/vaccines13060567

AMA Style

Tian T, Zhu Y, Shang K, Shi H, Xu R, Li M, Pu F, Kuang J, Ding J, Zhang F. FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella. Vaccines. 2025; 13(6):567. https://doi.org/10.3390/vaccines13060567

Chicago/Turabian Style

Tian, Tingting, Yuejie Zhu, Kaiyu Shang, Huidong Shi, Ruixue Xu, Mingzhe Li, Fuling Pu, Junyu Kuang, Jianbing Ding, and Fengbo Zhang. 2025. "FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella" Vaccines 13, no. 6: 567. https://doi.org/10.3390/vaccines13060567

APA Style

Tian, T., Zhu, Y., Shang, K., Shi, H., Xu, R., Li, M., Pu, F., Kuang, J., Ding, J., & Zhang, F. (2025). FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella. Vaccines, 13(6), 567. https://doi.org/10.3390/vaccines13060567

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop